Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 4Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 11Neoplasms 4Adenocarcinoma of Lung 4Brain Neoplasms 3Adenocarcinoma, Bronchiolo-Alveolar 3Neoplasm Metastasis 2NSCLC 2Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Diseases 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1Head and Neck Neoplasms 1EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors 1Carcinoma 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Gefitinib × Clear all
NCT02889692 2019-04-11

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Shanghai University of Traditional Chinese Medicine

Phase 3 Completed
23 enrolled
Thoracic

Lung Neoplasms, Neoplasms

NCT02929693 2019-04-11

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Shanghai University of Traditional Chinese Medicine

Phase 3 Unknown
198 enrolled
Tumor-Agnostic

Neoplasms

NCT00034879 2013-01-04

Iressa Expanded Access Program (EAP)

AstraZeneca

Phase 3 Completed
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00635973 2009-04-22

Open-Label Extension of Other SZ1839 (Iressa) Trials

AstraZeneca

Phase 3 Completed
100 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡